Stability is fine. Same BS resurfaces from shorts that came in the deleted forbes article
Funny one of the short grunts is posting about stability again - a clear sign they are nervous into data - same issue from the article that was in the web in the fall that Forbes deleted same day for inaccuracy. Remember company has stated publicly that stability is not a problem and here is what JMP said:
The issue of stability was raised previously last fall and JMP Securities issued this comment:
• Drug stability does not concern us. The second point of the debate raised by the Forbes article was related to the stability of palifosfamide and the commercial implications. Developing a stable formulation of palifosfamide has been a key focus during the development program and Ziopharm reiterated that it has no issues with drug stability. We do not view this issue as a hurdle to clinical or regulatory success and management stated to us that, while continuing to seek improvements is a focus, the palifosfamide-tris formulation being used in Phase III is commercially viable.
As we stated on page 1, the stability of palifosfamide has been a key development achievement for Ziopharm. There have been more than 300 clinical sites worldwide involved in palifosfamide trials, ranging from large academic institutions to independent oncology centers. We are confident that the current formulation has no stability issues that would impact commercial adoption should the Phase III data be supportive of regulatory approval.
Funny you mention the Forbes article. ZIOP really never recovered from that debacle. What really happened there? It comes down to the science. I owned several thousand shares of PCYC and call options when it was at 12. Lots of naysayers back then, look at the stock now. If I only held!!!